Cover Image

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION

The article presents the data from an open, two-stage, multicenter study on the efficacy and safety evaluation of a combined drug (a fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg) in the complex therapy in COVID-19 patients.The aim of the study was to assess the safety, tolerability...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. A. Balykova (Author), N. M. Selezneva (Author), E. I. Gorshenina (Author), O. I. Shepeleva (Author), N. V. Kirichenko (Author), E. N. Simakina (Author), K. B. Kolontarev (Author), D. Yu. Pushkar (Author), D. N. Zemskov (Author), K. Ya. Zaslavskaya (Author), S. M. Noskov (Author), A. V. Taganov (Author), P. A. Bely (Author)
Format:	Book
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
by: L. A. Balykova, et al.
Published: (2022)

Post-exposure prophylaxis of COVID-19: results of double-blind, placebo-controlled, multicenter clinical study evaluation of efficacy and safety of double-stranded sodium salt RNA drug
by: L. A. Balykova, et al.
Published: (2023)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023)

CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY
by: D. N. Zemskov, et al.
Published: (2022)

Analysis of cytokine response characteristics and immunopathogenetic effects of double-stranded sodium salt RNA-based drug for postexposure prophylaxis against novel coronavirus infection: double-blind, placebo-controlled trial
by: O. A. Radaeva, et al.
Published: (2023)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

EFFICACY AND SAFETY OF ORIGINAL DRUG BASED ON HEXAPEPTIDE SUCCINATE IN COMPLEX COVID-19 THERAPY IN ADULTS HOSPITALIZED PATIENTS
by: L. A. Balykova, et al.
Published: (2023)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
by: Aili Lu, et al.
Published: (2023)

Managing nirmatrelvir/ritonavir during COVID-19: pharmacists' experiences from the Perak state of Malaysia
by: Chee Tao Chang, et al.
Published: (2022)

Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023)

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
by: Sheng En Alexius Matthias Soh, et al.
Published: (2024)

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
by: Hui Li, et al.
Published: (2023)

EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)
by: L. A. Balykova, et al.
Published: (2020)

STUDY OF LONG-TERM CLINICAL AND PATHOGENETIC EFFECTS OF FAVIPIRAVIR-BASED ANTI-VIRAL DRUG IN PATIENTS WITH METABOLIC SYNDROME IN POST-COVID PERIOD
by: O. A. Radaeva, et al.
Published: (2022)

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
by: Chih-Wei Lin, et al.
Published: (2023)

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
by: Jiayi Yan, et al.
Published: (2023)

Estudio de utilización de nirmatrelvir/ritonavir en tres centros de atención primaria durante 2022
by: José Miguel Sotoca-Momblona, et al.
Published: (2023)

A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir
by: Jiantao Zheng, et al.
Published: (2023)

Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study
by: Takeshi Tomida, et al.
Published: (2024)

Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series
by: Hanako Naganawa, et al.
Published: (2024)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
by: Eun-Jeong Kwon, et al.
Published: (2022)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023)

Pharmacokinetics Profile and Genetics of Double Antiviral Therapy with Remdesivir and Nirmatrelvir/Ritonavir for Prolonged COVID-19 in Patients Treated with Rituximab: A Real-Life Study and Literature Review
by: Ilaria De Benedetto, et al.
Published: (2024)

Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide
by: A. S. Ametov, et al.
Published: (2024)

Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
by: Chenxiao Jiang, et al.
Published: (2024)

Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
by: Yu Xiong, et al.
Published: (2023)

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
by: Ee Vien Low, et al.
Published: (2024)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
by: Jinhua Huang, et al.
Published: (2022)

Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
by: Xue Zhong, et al.
Published: (2023)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024)

Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
by: Nan Shang, et al.
Published: (2024)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023)